Latent autoimmune diabetes in adults

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 12, 2009, Pages 4635-4644

  Naik, Ramachandra G ^a   Brooks Worrell, Barbara M ^b   Palmer, Jerry P ^b  

^a Charles River Clinical Services Northwest Inc   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; AUTOANTIBODY; C PEPTIDE; CD3 ANTIBODY; CELL PROTEIN; DIAMYD; GAMMA INTERFERON; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE ALUM; GLUTAMATE DECARBOXYLASE ANTIBODY; GLUTAMATE DECARBOXYLASE VACCINE; HLA DQB1 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; PANCREAS ISLET CELL ANTIBODY; PEPTIDE VACCINE; ROSIGLITAZONE; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIBODY DETECTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARBOXY TERMINAL SEQUENCE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DIABETIC PATIENT; DISEASE MODEL; DRUG DOSE ESCALATION; DRUG SAFETY; FAMILY HISTORY; GENE CONTROL; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; KETOACIDOSIS; LATENT AUTOIMMUNE DIABETES; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 73249122485     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1120     Document Type: Review

References (111)

1. Kuzuya T, Matsuda A 1997 Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. Diabetes Care 20:219-220
2. Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, O'Brien PC, Melton 3rd LJ 1997 The classification of diabetes by clinical and C-peptide criteria: a prospective population-based study. Diabetes Care 20:198-201
3. Van der Auwera B, Van Waeyenberge C, Schuit F, Heimberg H, Vandewalle C, Gorus F, Flament J 1995 DRB1*0403 protects against IDDM in Caucasians with the high-risk heterozygous DQA1*0301-DQB1*0302/ DQA1*0501-DQB1*0201 genotype. Belgian Diabetes Registry. Diabetes 44:527-530
4. Neifing JL, Greenbaum CJ, Kahn SE, McCulloch DK, Barmeier H, Lernmark A, Palmer JP 1993 Prospective evaluation of β-cell function in insulin autoantibody-positive relatives of insulin-dependent diabetic patients. Metabolism 42:482-486
5. McCulloch DK, Palmer JP 1991 The appropriate use of B-cell function testing in the preclinical period of type 1 diabetes. Diabet Med 8:800-804
6. Alberti KG, Zimmet PZ 1998 Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 15:539-553
7. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 1997 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
8. Naik RG, Palmer JP 1997 Late-onset type 1 diabetes. Curr Opin Endocrinol Diabetes 4:308-315
9. Bottazzo GF, Florin-Christensen A, Doniach D 1974 Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2:1279-1282
10. MacCuish AC, Irvine WJ, Barnes EW, Duncan LJP 1974 Antibodies to pancreatic islet cells in insulin-dependent diabetics with coexistent autoimmune disease. Lancet 2:1529-1531
11. Irvine WJ, Gray RS, McCallum CJ, Duncan LJP 1977 Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1:1025-1027
12. Zimmet PZ 1995 The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography. Diabetes Care 18:1050-1064
13. Kobayashi T 1994 Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: slowly progressive IDDM-the clinical characteristics and pathogenesis of the syndrome. Diabetes Res Clin Pract 24 Suppl:S95-S99
14. Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, Sugimoto T, Murase T, Kosaka K 1993 Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16:780-788
15. Groop LC, Bottazzo GF, Doniach D 1986 Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 17:1214-1219
16. Palmer JP, Hirsch IB 2003 What's in a name: latent autoimmune diabetes in adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 26:536-538
17. Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, Tuomi T, Cilio CM, Groop L 2008 Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 57:1433-1437
18. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP 2001 Islet cell antibodies and glutamic acid decarboxylase antibodies but not the clinical phenotype help to identify type 1 1/2 diabetes in patients presenting with type 2 diabetes. Metabolism 50:1008-1013
19. Juneja R, Palmer JP 1999 Type 1 1?2 diabetes: myth or reality. Autoimmunity 29:65-83
20. Naik RG, Palmer JP 2003 Latent autoimmune diabetes in adults (LADA). Rev Endocr Metab Disord 4:233-241
21. Borg H, Gottsäter A, Landin-Olsson M, Fernlund P, Sundkvist G 2001 High levels of antigen-specific islet antibodies predict future β-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 86:3032-3038
22. Urakami T, Miyamoto Y, Matsunaga H, Owada M, Kitagawa T 1995 Serial changes in the prevalence of islet cell antibodies and islet cell antibody titer in children with IDDM of abrupt or slow onset. Diabetes Care 18:1095-1099
23. Nakanishi K, Kobayashi T, Miyashita H, Okubo M, Sugimoto T, Murase T, Kosaka K, Hara M 1993 Relationships among residual β cells, exocrine pancreas, and islet cell antibodies in insulin-dependent diabetes mellitus. Metabolism 42:196-203
24. Yeung V, Chan JCN, Chow CC, Zimmet P, Cockrum CS, Antibodies to glutamic acid decarboxylase (anti-GAD) in Chinese IDDM patients. Proc 15th International Diabetes Federation Congress, Kobe, Japan, 1994, p 432
25. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC 2005 Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48:2206-2212
26. Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM 2005 Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age?. Diabetes 54:S62-S67
27. Rosenbloom AL 2003 Obesity, insulin resistance, β-cell autoimmunity, and the changing clinical epidemiology of childhood diabetes. Diabetes Care 26:2954-2956
28. Hathout EH, Thomas W, El-Shahawy M, Nahab F, Mace JW 2001 Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 107:E102
29. Umpaichitra V, Banerji MA, Castells S 2002 Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 15:525-530
30. Kahn SE 2001 The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058
31. Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, Davidson HW, Hutton JC 2008 SIC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann NY Acad Sci 1150:256-259
32. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR 1993 Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359-362
33. Hosszúfalusi N, Vatay A, Rajczy K, Prohászka Z, Pozsonyi E, Horváth L, Grosz A, Gerõ L, Madácsy L, Romics L, Karádi I, Füst G, Pánczél P 2003 Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452-457
34. Murao S, Kondo S, Ohashi J, Fujii Y, Shimizu I, Fujiyama M, Ohno K, Takada Y, Nakai K, Yamane Y, Osawa H, Makino H 2008 Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting Cpeptide levels predict β cell failure in patients with latent autoimmune diabetes in adults (LADA). A 5 year follow-up of the Ehime study. Diabetes Res Clin Pract 80:114-121
35. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS 2003 The Diabetes Prevention Trial-Type 1 Study Group: screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 88:103-108
36. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase HP, Eisenbarth GS 1996 Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 9:379-383
37. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS 1996 Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45:926-933
38. Mayer A, Fabien N, Gutowski MC, Dubois V, Gebuhrer L, Bienvenu J, Orgiazzi J, Madec AM 2007 Contrasting cellular and humoral autoimmunity associated with latent autoimmune diabetes in adults.Eur J Endocrinol 157:53-61
39. Zavala AV, Fabiano de Bruno LE, Cardoso AI, Mota AH, Capucchio M, Poskus E, Fainboim L, Basabe JC 1992 Cellular and humoral autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Diabetologia 35:1159-1164
40. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R 1997 UKPDS 25. Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350:1288-1293
41. Rowley MJ, Mackay IR, Chen QY, Knowles WJ, Zimmet PZ 1992 Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 41:548-551
42. Lohmann T, Kellner K, Verlohren HJ, Krug J, Steindorf J, Scherbaum WA, Seissler J 2001 Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 44:1005-1010
43. Borg H, Gottsäter A, Fernlund P, Sundkvist G 2002 A 12-year prospective study of the relationship between islet antibodies and β-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 51:1754-1762
44. van Deutekom AW, Heine RJ, Simsek S 2008 The islet autoantibody titers their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabet Med 25:117-125
45. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F, Bosi E 2007 High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30:932-938
46. Seissler J, de Sonnaville JJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, Lan MS, Notkins AL, Heine RJ, Scherbaum WA 1998 Immunological heterogeneity in type 1 diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 41:891-897
47. Hillman M, Törn C, Thorgeirsson H, Landin-Olsson M 2004 IgG4-subclass of glutamic acid decarboxylase antibody is more frequent in latent autoimmune diabetes in adults than in type 1 diabetes. Diabetologia 47:1984-1989
48. Hampe CS, Kockum I, Landin-Olsson M, Törn C, Ortqvist E, Persson B, Rolandsson O, Palmer J, Lernmark A 2002 GAD65 antibody epitope patterns of patients with type 1.5 differ from that of type 1 diabetes patients. Diabetes Care 25:1481-1482
49. Padoa CJ, Banga JP, Madec AM, Ziegler M, Schlosser M, Ortqvist E, Kockum I, Palmer J, Rolandsson O, Binder KA, Foote J, Luo D, Hampe CS 2003 Recombinant Fab of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 52:2689-2695
50. Desai M, Cull CA, Horton VA, Christie MR, Bonifacio E, Lampasona V, Bingley PJ, Levy JC, Mackay IR, Zimmet P, Holman RR, Clark A 2007 GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 50:2052-2060
51. Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R, Cucinotta D, Galluzzo A, Falorni A, Dotta F 2008 Identification of tyrosine phosphatase 2 (256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients. The Non-Insulin Requiring Autoimmune Diabetes (NIRAD) Study. Diabetes 57:1276-1283
52. Brooks-Worrell B, Dosch HM, Herold K, Seyfert V, Greenbaum CJ, Gitelman SE, Palmer JP 2004 Marked differences in T cell reactivity in recently diagnosed type 1 diabetes patients versus controls. Proc 12th International Congress of Immunology and 4th Annual Conference of the Federation of Clinical Immunology Societies, Montreal, Canada
53. Brooks-Worrell B, Warsen A, Palmer JP 2009 Improved T cell assay for identification of type 1 diabetes patients. J Immunol Methods 344:79-83
54. Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP 1999 Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 48:983-988
55. Ismail H, Wotring M, Kimmie C, Au L, Palmer JP, Brooks-Worrell BM 2007 T cell-positive antibody-negative phenotypic type 2 patients, a unique subgroup of autoimmune diabetes. Diabetes 56(S1):A325
56. Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JP 1996 Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J Immunol 157:5668-5674
57. Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JP 2001 Intermolecular antigen spreading occurs during the pre-clinical period of human type 1 diabetes. J Immunol 166:5265-5270
58. Roep BO, Arden SD, de Vries RR, Hutton JC 1990 T cell clones from a type 1 diabetic patient respond to insulin secretory granule proteins. Nature 345:632-634
59. Roep BO, Kallan AA, Duinkerken G, Arden SD, Hutton JC, Bruining GJ, de Vries RR 1995 T cell reactivity to β-cell membrane antigens associated with β cell destruction in IDDM. Diabetes 44:278-283
60. Roep BO 1996 T cell responses to autoantigens in IDDM: The search for the Holy Grail. Diabetes 45:1147-1156
61. Durinovic-Bellò I, Hummel M, Ziegler AG 1996 Cellular immune response to diverse islet cell antigens in IDDM. Diabetes 45:795-800
62. Goel A, Chiu H, Felton J, Palmer JP, Brooks-Worrell B 2007 T cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 56:2110-2115
63. Tree TI, Roep BO, Peakman M 2006 A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann NY Acad Sci 1079:9-18
64. Yang Z, Zhou Z, Huang G, Ling H, Yan X, Peng J, Li X 2007 The CD4+ regulatory T-cells is decreased in adults with latent autoimmune diabetes. Diabetes Res Clin Pract 76:126-131
65. The Diabetes Control and Complications Trial Research Group 1998 Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial.Arandomized, controlled trial. Ann Intern Med 128:517-523
66. Törn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohmé G, Lithner F, Littorin B, Nyström L, Scherstén B, Sundkvist G, Wibell L, Ostman J 2000 Prognostic factors for the course of β cell function in autoimmune diabetes. J Clin Endocrinol Metab 85:4619-4623
67. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G 1993 β-Cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16:902-910
68. Behme MT, Dupre J, Harris SB, Hramiak IM, Mahon JL 2003 Insulin resistance in latent autoimmune diabetes of adulthood. Ann NY Acad Sci 1005:374-377
69. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI 2004 Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 53:3193-3200
70. Chiu HK, Tsai EC, Juneja R, Stoever J, Brooks-Worrell B, Goel A, Palmer JP 2007 Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetes patients. Diabetes Res Clin Pract 77:237-244
71. Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S, Mackay IR 2000 Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 17:667-674
72. Hawa MI, Thivolet C, Mauricio D, Alemanno I, Cipponeri E, Collier D, Hunter S, Buzzetti R, de Leiva A, Pozzilli P, Leslie RD 2009 Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care 32:160-164
73. Donath MY, Ehses JA 2006 Type 1, type 1.5, and type 2 diabetes: NOD the diabetes we thought it was. Proc Natl Acad Sci USA 103:12217-12218
74. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA 2008 Islet inflammation in type 2 diabetes. Diabetes Care 31(Suppl 2):S161-S164
75. Pietropaolo M, Barinas-Mitchell E, Kuller LH 2007 The heterogeneity of diabetes. Unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes 56:1189-1197
76. Gleichmann H, Zörcher B, Greulich B, Gries FA, Henrichs HR, Betrams J, Kolb H 1984 Correlation of islet cell antibodies and HLA-DR phenotypes with diabetes mellitus in adults. Diabetologia 27:90-92
77. Chiu HK, Palmer JP 2004 Autoimmune diabetes: more than just one flavor? J Endocrinol Invest 27:480-484
78. Sanjeevi CB, Gambelunghe G, Falorni A, Shtauvere-Brameus A, Kanungo A 2002 Genetics of latent autoimmune diabetes in adults. Ann NY Acad Sci 958:107-111
79. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissén M, Ehrnström BO, Forsén B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC 1999 Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157
80. Cosentino A, Gambelunghe G, Tortoioli C, Falorni A 2002 CTLA-4 gene polymorphism contributes to the genetic risk for latent autoimmune diabetes in adults. Ann NY Acad Sci 958:337-340
81. Cerrone GE, Caputo M, Lopez AP, González C, Massa C, Cédola N, Targovnik HM, Frechtel GD 2004 Variable number of tandem repeats of the insulin gene determines susceptibility to latent autoimmune diabetes in adults. Mol Diagn 8:43-49
82. Törn C, Gupta M, Nikitina Zake L, Sanjeevi CB, Landin-Olsson M 2003 Heterozygosity for MICA5.0/MICA5.1 and HLA-DR3-DQ2/DR4-DQ8 are independent genetic risk factors for latent autoimmune diabetes in adults. Hum Immunol 64:902-909
83. Vatay A, Rajczy K, Pozsonyi E, Hosszúfalusi N, Prohászka Z, Füst G, Karádi I, Szalai C, Grósz A, Bártfai Z, Pánczél P 2002 Differences in the genetic background of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus. Immunol Lett 84:109-115
84. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P 2007 A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881-885
85. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M 2007 A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341-1345
86. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Boström K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Råstam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjögren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R, Blumenstiel B, Parkin M, Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Ricke D, Purcell S 2007 Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331-1336
87. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney AS, McCarthy MI, Hattersley AT 2007 Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336-1341
88. Staiger H, Machicao F, Stefan N, Tschritter O, Thamer C, Kantartzis K, Schäfer SA, Kirchhoff K, Fritsche A, Häring HU 2007 Polymorphisms within novel risk loci for type 2 diabetes determine β-cell function. PloS ONE 2:e832
89. Kirchhoff K, Machicao F, Haupt A, Schäfer SA, Tschritter O, Staiger H, Stefan N, Häring HU, Fritsche A 2008 Polymorphisms in the TCF7L2, CDKAL1, and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 51:597-601
90. Boesgaard TW, Zilinskaite J, Vänttinen M, Laakso M, Jansson PA, Hammarstedt A, Smith U, Stefan N, Fritsche A, Häring H, Hribal M, Sesti G, Zobel DP, Pedersen O, Hansen T 2008 The common SLC30A8 Arg325Trp variant is associated with reduced firstphase insulin release in 846 non-diabetic offspring of type 2 diabetes patients: the EUGENE2 study. Diabetologia 51:816-820
91. Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, Walters J, Eisenbarth GS, Davidson HW, Hutton JC 2008 A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 57:2693-2697
92. Grill V, Persson G, Carlsson S, Norman A, Alvarsson M, Ostensson CG, Svanström L, Efendic S 1999 Family history of diabetes in middle-age Swedish men is a gender unrelated factor which associates with insulinopenia in newly diagnosed diabetes subjects. Diabetologia 42:15-23
93. Meigs JB, Cupples LA, Wilson PW 2000 Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 49:2201-2207
94. Bonifacio E, Hummel M, Walter M, Schmid S, Ziegler AG 2004 IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care 27:2695-2700
95. Carlsson S, Midthjell K, Grill V 2007 Influence of family history of diabetes on incidence and prevalence of latent autoimmune diabetes of the adult: results from the Nord-Trøndelag Health Study. Diabetes Care 30:3040-3045
96. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA 2002 Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698
97. Bertrand S, De Paepe M, Vigeant C, Yale JF 1992 Prevention of adoptive transfer in BB rats by prophylactic insulin treatment. Diabetes 41:1273-1277
98. Gotfredsen CF, Buschard K, Frandsen EK 1985 Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 28:933-935
99. Kobayashi T 2001 Multicenter prevention trial of slowly progressive IDDM with small dose of insulin (the Tokyo Study). Diabetes Metab Res Rev 17 (Suppl):S29
100. Kobayashi T, Maruyama T, Shimada A, Kasuga A, Kanatsuka A, Takei I, Tanaka S, Yokoyama J 2002 Insulin intervention to preserve β cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann NY Acad Sci 958:117-130
101. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C 2004 Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-g, reduces acute inflammation. Eur J Pharmacol 483:79-93
102. Ramakers JD, Verstege MI, Thuijls G, Te Velde AA, Mensink RP, Plat J 2007 The PPARγ agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J Clin Immunol 27:275-283
103. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P 2004 Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89:2728-2735
104. Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, Nam M, Chung CH, Lee KW, Nam CM, Lee HC 2007 Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-β in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 66:282-289
105. Abdin AA, Baalash AA, Homooda HE 26 March 2009 Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focusoninsulin resistance and inflammatory markers. J Diabetes Complications 10.016/j.jdiacomp.2009.01.005
106. Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC, Cozzolino D, Assaloni R, Merante D, Ceriello A, Giugliano D 2006 Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29:1071-1076
107. Yang Z, Zhou Z, Li X, Huang G, Lin J 2009 Rosiglitazone preserves islet β-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract 83:54-60
108. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY 2007 Interleukin-1 receptor antagonist in type 2 diabetes. N Engl J Med 356:1517-1526
109. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmér M, Harris RA, Robertson JA, Lernmark A 2005 Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19:238-246
110. Ludvigsson J, FaresjöM, Hjorth M, Axelsson S, Che ramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R 2008 GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359:1909-1920
111. Agardh CD, Lynch KF, Palmér M, Link K, Lernmark A 2009 GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 10.1007/s00125-009-1371-2